Value-Added Schizophrenia Round-Up: Luye Expects Chinese First With US Risperidone
Several firms are making progress on added-value risperidone formulations: Luye Pharma anticipates FDA approval for its extended-release microspheres; Rovi is moving towards a US 505(b)(2) filing for its Doria once-monthly formulation; and Indivior has introduced its Perseris subcutaneous suspension in the US.
You may also be interested in...
Luye Pharma says it is making sound progress in developing a pipeline of added-value injectables and transdermal patches, while clinical trials for two biosimilars are also moving forward.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.